CERN Cerner Corporation

Cerner and Elligo to Make Clinical Trials Accessible for Health Systems of All Sizes

Cerner and Elligo to Make Clinical Trials Accessible for Health Systems of All Sizes

KANSAS CITY, Mo., Dec. 08, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: CERN), a global health care technology company, today announced an investment in , a leading integrated research organization that enables clinical trials with nationwide community-based health care practices. Cerner representatives will also join Elligo’s board of directors. As a result of this investment, Cerner plans to enter into a commercial agreement to expand the data and tools available in the to offer additional clinical trial resources to community and rural hospitals and physician practices. This collaboration is expected to help accelerate clinical research timeframes, make clinical trials more broadly and easily accessible and reduce the costs associated with bringing a therapy to market.

“At the beginning of the year, we launched a bold push with our provider clients to change the pace and cost of clinical trials. Today, 51 health systems are part of our Learning Health Network,” said Donald Trigg, president, Cerner. “Elligo shares our passion for making clinical trial opportunities accessible to every provider and patient. Our collaboration will accelerate that shared mission in the quarters ahead.”

Health systems face significant obstacles such as patient recruitment, costs and access to clinical trial resources. Today, for example, the drug development process takes and . Cerner and Elligo will focus on helping reduce those obstacles health systems face to make clinical trials become more of a reality – no matter the size, location or academic standing.

Additionally, most clinical trials are executed in large, urban areas with homogenous trial populations, which offer insights that may not be broadly applicable to all patients in need of the therapies. Clinical trial resources can offer funded research opportunities for health care organizations as well as access to trial therapies for patients who need it most, including those in minority populations and rural communities. This could result in outcomes that are more representative of diverse populations and a potential increase in drug safety through post-market surveillance capabilities.

As one of the largest health networks for clinical research, Elligo works to bring research as a care option to as many participants as possible by offering innovative, patient-centric solutions within the practices of trusted physicians.

“Elligo’s mission is to bring clinical research to everyone, but today’s clinical research processes are obsolete and expensive,” said ., CEO, Elligo. “Our collaboration with Cerner will be designed to help transform the research process by optimizing operations, focusing on the patient and producing the regulatory-grade data needed to inform decision-making.”

Financial terms were not disclosed.

Perella Weinberg Partners served as exclusive financial advisor to Elligo and Goodwin Procter LLP served as legal counsel to Elligo in connection with the investment. Stinson served as legal counsel for Cerner.

About Cerner

’s health technologies connect people and information systems at thousands of contracted provider facilities worldwide dedicated to creating smarter and better care for individuals and communities. Recognized globally for innovation, Cerner assists clinicians in making care decisions and assists organizations in managing the health of their populations. The company also offers an integrated clinical and financial system to help manage day-to-day revenue functions, as well as a wide range of services to support clinical, financial and operational needs, focused on people. For more information, visit ,  or connect on , , ,  or . Nasdaq: CERN. Health care is too important to stay the same.

About Elligo Health Research

Elligo Health Research, a healthcare-enabling research organization, uses electronic health records and the trusted patient and physician relationship to ensure all patients have access to clinical research as a care option. Powered by our Goes Direct® approach and novel IntElligo® Research Stack clinical technology, our team provides access to the best healthcare experts, patients, and research technologies. We engage physicians and patients who otherwise would not participate in clinical research and accelerate the development of new pharmaceutical, biotechnology, and medical device and diagnostic products. Learn more at .

Media Contacts:

Stephanie Greenwood, Cerner Public Relations,

Jane Byram, Elligo - SCORR Marketing, (512) 626-2758,



EN
08/12/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cerner Corporation

CERNER sees an upgrade to Slightly Positive due to a better fundamenta...

The general evaluation of CERNER (US), a company active in the Software industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date December 14, 2021, the closing price was USD 77.26 and...

 PRESS RELEASE

Cerner Announces Increased Quarterly Dividend

Cerner Announces Increased Quarterly Dividend Dividend of $0.27 per issued and outstanding share reflects 23% increase KANSAS CITY, Mo., Dec. 10, 2021 (GLOBE NEWSWIRE) --  (NASDAQ: CERN), a global healthcare technology company, today announced that its board of directors declared a cash dividend to stockholders of $0.27 per issued and outstanding share, up 23 percent from the prior quarterly dividend of $0.22. The cash dividend will be payable January 11, 2022, to shareholders of record as of the close of business December 27, 2021. Cerner intends to pay regular quarterly cash dividend...

 PRESS RELEASE

Cerner Names Nasim Afsar, MD MBA as Company’s First Chief Health Offic...

Cerner Names Nasim Afsar, MD MBA as Company’s First Chief Health Officer Experienced Clinical Executive to Lead Patient and Caregiver Experiences KANSAS CITY, Mo., Nov. 16, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: CERN), a global healthcare technology company, today announced Nasim Afsar, MD, MBA, MHM, as the company’s first Chief Health Officer, effective January 2022. In this new role, Dr. Afsar will lead Cerner’s more than 1,000 healthcare professionals who provide insight and guidance to product development and improving the lives of patients and caregivers. She will also lead the quality...

 PRESS RELEASE

Cerner Reports Third Quarter 2021 Results

Cerner Reports Third Quarter 2021 Results Delivers Strong Results Across Key MetricsGAAP Operating Margin and Diluted EPS Lower; Adjusted Operating Margin and Adjusted Diluted EPS Both up Sharply vs. Year-Ago QuarterFull-Year Guidance Increased KANSAS CITY, Mo., Oct. 29, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: CERN) today announced results for the 2021 third quarter that ended September 30, 2021. The third quarter 2021 earnings release can be viewed as well as on the company’s website at . Cerner will host an earnings conference call to provide additional detail on the Company’s results a...

 PRESS RELEASE

Cerner Enviza Aims To Accelerate Therapies And Improve Patient Outcome...

Cerner Enviza Aims To Accelerate Therapies And Improve Patient Outcomes Combining decades of healthcare, life sciences and collaborative research to transform the way care is delivered KANSAS CITY, Mo., Oct. 26, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: CERN), a global healthcare technology company, announces the launch of a new operating unit, SM, that offers data-driven solutions and research services to help bring clarity to multi-dimensional data through real-world evidence and insights. The combined expertise of the Cerner and Kantar Health teams is expected to help accelerate discovery, ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch